M-CSF accelerates neointimal formation in the early phase after vascular injury in mice: the critical role of the SDF-1-CXCR4 system

Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):283-9. doi: 10.1161/01.ATV.0000250606.70669.14. Epub 2006 Oct 19.

Abstract

Objective: Since the macrophage colony-stimulating factor (M-CSF) has been shown to stimulate differentiation and proliferation of monocyte/macrophage lineage and to be involved in the process of neointimal formation after vascular injury, we tested the effects of M-CSF on the recruitment of bone marrow-derived progenitor cells in neointimal formation after vascular injury in mice.

Methods and results: Wire-mediated vascular injury was produced in the femoral artery of C57BL/6 mice. Recombinant human M-CSF [500 microg/(kg x day)] or saline (control) was administered for 10 consecutive days, starting 4 days before the injury. Treatment with M-CSF accelerated neointimal formation in the early phase after injury, and this neointimal lesion mainly consisted of bone marrow-derived cells. M-CSF treatment had no effect on the mobilization of endothelial progenitor cells (EPCs: CD34+/Flk-1+) and reendothelialization after injury. The stromal cell-derived factor-1 (SDF-1) was markedly expressed in the neointima and media after injury, whereas CXCR4+ cells were observed in the neointima. Further, a novel CXCR4 antagonist, AMD3100, significantly attenuated the M-CSF-induced neointimal formation.

Conclusions: These findings suggest that M-CSF accelerated neointimal formation after vascular injury via the SDF-1-CXCR4 system, and the inhibition of this system has therapeutic potential for the treatment of cardiovascular diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzylamines
  • Bone Marrow Cells / cytology
  • Bone Marrow Cells / drug effects
  • Bone Marrow Cells / physiology
  • Cell Differentiation / drug effects*
  • Cell Differentiation / physiology
  • Cell Proliferation / drug effects
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / physiology
  • Chemokine CXCL12
  • Chemokines, CXC / genetics
  • Chemokines, CXC / physiology*
  • Cyclams
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiology
  • Gene Expression Regulation / drug effects
  • Heterocyclic Compounds / pharmacology
  • Interleukin-10 / genetics
  • Interleukin-10 / physiology
  • Interleukin-6 / genetics
  • Interleukin-6 / physiology
  • Macrophage Colony-Stimulating Factor / pharmacology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Receptors, CXCR4 / antagonists & inhibitors
  • Receptors, CXCR4 / drug effects
  • Receptors, CXCR4 / genetics
  • Receptors, CXCR4 / physiology*
  • Signal Transduction / physiology
  • Stem Cells / cytology
  • Stem Cells / drug effects*
  • Stem Cells / physiology
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / physiology
  • Tunica Intima / cytology
  • Tunica Intima / drug effects
  • Tunica Intima / physiology

Substances

  • Benzylamines
  • CXCL12 protein, human
  • CXCR4 protein, mouse
  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Chemokine CXCL12
  • Chemokines, CXC
  • Cxcl12 protein, mouse
  • Cyclams
  • Heterocyclic Compounds
  • Interleukin-6
  • Receptors, CXCR4
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Macrophage Colony-Stimulating Factor
  • plerixafor